HRP20050035B1 - Kristalniäśni 2,5-dion-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirol monohidroklorid - Google Patents

Kristalniäśni 2,5-dion-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirol monohidroklorid

Info

Publication number
HRP20050035B1
HRP20050035B1 HRP20050035AA HRP20050035A HRP20050035B1 HR P20050035 B1 HRP20050035 B1 HR P20050035B1 HR P20050035A A HRP20050035A A HR P20050035AA HR P20050035 A HRP20050035 A HR P20050035A HR P20050035 B1 HRP20050035 B1 HR P20050035B1
Authority
HR
Croatia
Prior art keywords
indol
piperidin
ylmethyl
dione
pyridin
Prior art date
Application number
HRP20050035AA
Other languages
English (en)
Croatian (hr)
Inventor
Julie Kay Bush
Margaret Mary Ful
Susan Marie Reutzel-Edens
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42799191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050035(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20050035A2 publication Critical patent/HRP20050035A2/hr
Publication of HRP20050035B1 publication Critical patent/HRP20050035B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20050035AA 2002-07-12 2003-07-08 Kristalniäśni 2,5-dion-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirol monohidroklorid HRP20050035B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39597602P 2002-07-12 2002-07-12
PCT/US2003/019548 WO2004006928A1 (en) 2002-07-12 2003-07-08 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride

Publications (2)

Publication Number Publication Date
HRP20050035A2 HRP20050035A2 (en) 2005-04-30
HRP20050035B1 true HRP20050035B1 (hr) 2013-07-31

Family

ID=42799191

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050035AA HRP20050035B1 (hr) 2002-07-12 2003-07-08 Kristalniäśni 2,5-dion-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirol monohidroklorid

Country Status (21)

Country Link
US (2) US8114901B2 (enExample)
EP (1) EP1523313B1 (enExample)
JP (2) JP4771356B2 (enExample)
KR (1) KR100687165B1 (enExample)
CN (1) CN100430058C (enExample)
AU (1) AU2003280958B9 (enExample)
CA (1) CA2393720C (enExample)
DE (1) DE60317675T2 (enExample)
EA (1) EA007463B1 (enExample)
EC (1) ECSP055537A (enExample)
ES (1) ES2295605T3 (enExample)
HR (1) HRP20050035B1 (enExample)
IL (1) IL165747A (enExample)
NO (1) NO330254B1 (enExample)
NZ (1) NZ537137A (enExample)
PE (1) PE20040652A1 (enExample)
PL (1) PL373046A1 (enExample)
TW (1) TWI315667B (enExample)
UA (1) UA78801C2 (enExample)
WO (1) WO2004006928A1 (enExample)
ZA (1) ZA200500065B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101345002B1 (ko) 2005-01-21 2013-12-31 아스텍스 테라퓨틱스 리미티드 제약 화합물
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2408372B1 (en) 2009-03-02 2019-01-09 Seventh Sense Biosystems, Inc. Devices associated with blood sampling
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
ES2561824T3 (es) 2010-07-16 2016-03-01 Seventh Sense Biosystems, Inc. Ambiente a baja presión para dispositivos de transferencia de fluidos
WO2012044689A1 (en) * 2010-09-30 2012-04-05 Wisconsin Alumni Research Foundation (20R,25S)-2-METHYLENE-19,26-DINOR-1α, 25-DIHYDROXYVITAMIN D3 IN CRYSTALLINE FORM
ES2565805T3 (es) 2010-11-09 2016-04-07 Seventh Sense Biosystems, Inc. Sistemas e interfaces para el muestreo de sangre
KR102237667B1 (ko) 2011-04-29 2021-04-12 세븐쓰 센스 바이오시스템즈, 인크. 유체들의 전달 및/또는 수용
KR20190086655A (ko) 2016-06-17 2019-07-23 유니버시다드 데 로스 안데스 저온-적응된 해양생물종의 천연 공급원으로부터 유래된 젤라틴 중합체 및 그것의 용도
TWI855386B (zh) 2016-08-10 2024-09-11 瑞士商赫孚孟拉羅股份公司 包含Ａｋｔ蛋白質激酶抑制劑之醫藥組合物
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN116199590B (zh) * 2022-12-26 2024-12-24 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017182A1 (en) * 1993-12-23 1995-06-29 Eli Lilly And Company Protein kinase c inhibitors
WO2001030331A2 (en) * 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
WO2002002116A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
WO2002002094A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3625738A1 (de) 1986-07-30 1988-02-11 Goedecke Ag 2-acyloxypropylamin-derivate, verfahren zu deren herstellung und deren verwendung
US4785085A (en) 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4808613A (en) 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
DE3752123T2 (de) 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
DE3803620A1 (de) 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
US5380746A (en) 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE4243321A1 (de) 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
SE501711C2 (sv) * 1993-09-08 1995-05-02 Jimek Int Ab Sprayrör för en duktvättanordning vid en tryckpress
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
PE91598A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
WO2001009116A2 (en) * 1999-07-29 2001-02-08 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
RU2004135382A (ru) * 2002-06-05 2005-06-27 Янссен Фармацевтика Н.В. (Be) Замещенные пирролины в качестве ингибиторов киназы

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017182A1 (en) * 1993-12-23 1995-06-29 Eli Lilly And Company Protein kinase c inhibitors
WO2001030331A2 (en) * 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
WO2002002116A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
WO2002002094A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy

Also Published As

Publication number Publication date
DE60317675D1 (de) 2008-01-03
IL165747A (en) 2010-05-17
AU2003280958A1 (en) 2004-02-02
HRP20050035A2 (en) 2005-04-30
HK1075839A1 (en) 2005-12-30
AU2003280958B8 (en) 2009-02-19
CA2393720A1 (en) 2004-01-16
EA007463B1 (ru) 2006-10-27
CN100430058C (zh) 2008-11-05
US20050288332A1 (en) 2005-12-29
UA78801C2 (en) 2007-04-25
PE20040652A1 (es) 2004-10-05
TWI315667B (en) 2009-10-11
EP1523313B1 (en) 2007-11-21
KR20050021453A (ko) 2005-03-07
EP1523313A1 (en) 2005-04-20
NO330254B1 (no) 2011-03-14
AU2003280958B2 (en) 2008-12-18
JP2006502115A (ja) 2006-01-19
US20070270465A1 (en) 2007-11-22
NO20050676L (no) 2005-02-09
ES2295605T3 (es) 2008-04-16
JP5242718B2 (ja) 2013-07-24
DE60317675T2 (de) 2008-10-30
WO2004006928A1 (en) 2004-01-22
KR100687165B1 (ko) 2007-02-27
IL165747A0 (en) 2006-01-15
CN1668304A (zh) 2005-09-14
JP4771356B2 (ja) 2011-09-14
CA2393720C (en) 2010-09-14
JP2011144182A (ja) 2011-07-28
EA200500191A1 (ru) 2005-06-30
AU2003280958B9 (en) 2009-07-02
NZ537137A (en) 2007-11-30
TW200408392A (en) 2004-06-01
ECSP055537A (es) 2005-03-10
PL373046A1 (en) 2005-08-08
ZA200500065B (en) 2006-03-29
US8114901B2 (en) 2012-02-14

Similar Documents

Publication Publication Date Title
HRP20050035B1 (hr) Kristalniäśni 2,5-dion-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirol monohidroklorid
NO20160131A1 (no) Farmasøytisk sammensetning omfattende en polymorf form av 3-(4-amino-1-okso-1,3 dihydro-isoindol-2-yl)-piperidin-1,6-dion
MXPA02005844A (es) Inhibidores de cinasas de proteina.
DK1379520T3 (da) N-substituerede ikke-aryl-heterocykliske NMDA/NR2B-antagonister
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
HRP20020306B1 (en) 6-position substituted indole, production and use thereof as a medicament
ATE328874T1 (de) Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
DK0658159T3 (da) Aryliden- og heteroaryliden-oxindol-derivater som tyrosinkinaseinhibitorer
CA2399358A1 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
DK0772603T3 (da) Substituerede pyrimidinforbindelser og deres anvendelse
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
BR0213185A (pt) Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase
BRPI0407841A (pt) inibidores heterocìclicos de quinase
EP1501359A4 (en) IMMUNOSTIMULATING OLIGONUCLEOTIDE-CONTAINING COMPOSITIONS AND USES THEREOF FOR IMPROVING FC-RECEPTOR-MEDIATED IMMUNOTHERAPIES
MY138934A (en) Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
BR0315092A (pt) Derivados de piperidina como inibidores de ccr5
DE602005005638D1 (de) 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-on-derivate als pde4-inhibitoren
CR7650A (es) MONOCLORHIDRATO DE 2,5-DIONA-3(-1METIL-1H-INDOL-3-iL)-4-[1-(PIRIDIN-2-ILMETIL) PIPERIDIN-4-iL)-1H-INDOL-3-iL)]-1H-PIRROL CRISTALINO
AR107852A2 (es) Derivados de pirrol como inhibidor de secreción ácida
TH64677A (th) คริสทาลไลน์ 2,5-ไดโอน-3-(1-เมทธิล-1h-อินดอล-3-อิล)-4-[1-ไพริดิน-2-อิลเมทธิล) ไพเพอริดิม-4-อิล]1h-อินดอล-3-อิล]-1h-ไพร์โรล โมโน-ไฮโดรคลอไรด์
SG145574A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20140703

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20150708